

## Clinical Policy: Interferon Gamma- 1b (Actimmune)

Reference Number: LA.PHAR.52

Effective Date:

Last Review Date: 06.21

Line of Business: Medicaid

Coding Implications

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

### Description

Interferon gamma-1b (Actimmune<sup>®</sup>) is a recombinant form of gamma interferon.

### FDA Approved Indication(s)

Actimmune is indicated for:

- Reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD)
- Delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO)

### Policy/Criteria

Prior authorization is required. Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Actimmune is medically necessary when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Chronic Granulomatous Disease (must meet all):

1. Diagnosis of CGD;
2. Age  $\geq$  1 year;
3. Prescribed by or in consultation with a hematologist or infectious disease specialist;
4. Dose does not exceed one of the following (a or b):
  - a. Body surface area (BSA)  $> 0.5 \text{ m}^2$ : 50 mcg/m $^2$  three times weekly;
  - b. BSA  $\leq 0.5 \text{ m}^2$ : 1.5 mcg/kg three times weekly.

##### Approval duration:

Medicaid – 6 months

##### B. Severe Malignant Osteopetrosis (must meet all):

1. Diagnosis of SMO (also known as autosomal recessive osteopetrosis);
2. Prescribed by or in consultation with an endocrinologist or rheumatologist;
3. Age  $\geq$  1 month;
4. Dose does not exceed one of the following (a or b):
  - a. BSA  $> 0.5 \text{ m}^2$ : 50 mcg/m $^2$  three times weekly;
  - b. BSA  $\leq 0.5 \text{ m}^2$ : 1.5 mcg/kg three times weekly.

## CLINICAL POLICY

### Interferon Gamma-1b

**Approval duration:**  
**Medicaid – 6 months**

C. **Mycosis Fungoides, Sezary Syndrome (off-label) (must meet all):**

1. **Diagnosis of mycosis fungoides or Sezary syndrome;**
2. **Prescribed by or in consultation with an oncologist;**
3. **Age ≥ 18 years;**
4. **Request meets one of the following (a, b, or c):\***
  - a. **BSA > 0.5 m<sup>2</sup>: Dose does not exceed 50 mcg/m<sup>2</sup> three times weekly;**
  - b. **BSA ≤ 0.5 m<sup>2</sup>: Dose does not exceed 1.5 mcg/kg three times weekly;**
  - c. **Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).**

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:**  
**Medicaid – 6 months**

D. **Other diagnoses/indications**

1. **Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.**

## II. **Continued Therapy**

A. **All Indications in Section I (must meet all):**

1. **Member meets one of the following (a or b):**
  - a. **Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;**
  - b. **Documentation supports that member is currently receiving Actimmune for mycosis fungoides or Sezary syndrome and has received this medication for at least 30 days;**
2. **Member is responding positively to therapy;**
3. **If request is for a dose increase, request meets one of the following (a, b, or c):**
  - a. **BSA > 0.5 m<sup>2</sup>: New dose does not exceed 50 mcg/m<sup>2</sup> three times weekly;**
  - b. **BSA ≤ 0.5 m<sup>2</sup>: New dose does not exceed 1.5 mcg/kg three times weekly;**
  - c. **New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).**

**Approval duration:**  
**Medicaid – 6 months**

B. **Other diagnoses/indications (must meet 1 or 2):**

1. **Currently receiving medication via Louisiana Healthcare Connections benefit and documentation supports positive response to therapy.**  
**Approval duration: Duration of request or 6 months (whichever is less); or**
2. **Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.**

## CLINICAL POLICY

### Interferon Gamma-1b

#### **III. Diagnoses/Indications for which coverage is NOT authorized:**

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy –LA.PMN.53 for Medicaid, or evidence of coverage documents.

#### **IV. Appendices/General Information**

##### Appendix A: Abbreviation/Acronym Key

**BSA:** body surface area

**CGD:** chronic granulomatous disease

**FDA:** Food and Drug Administration

**SMO:** severe, malignant osteopetrosis

##### Appendix B: Therapeutic Alternatives

Not applicable

##### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to interferon gamma, *E. coli* derived products, or any component of the product
- Boxed warning(s): none reported

#### **V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
<u>CGD, SMO</u>	<u>BSA &gt; 0.5 m<sup>2</sup>: 50 mcg/m<sup>2</sup> SC TIW</u> <u>BSA ≤ 0.5 m<sup>2</sup>: 1.5 mcg/kg/dose SC TIW</u>	<u>See dosing regimen</u>

#### **VI. Product Availability**

Single-use vial for injection: 100 mcg (2 million IU)/0.5 ml

#### **VII. References**

- Actimmune Prescribing Information. Lake Forest, IL: Horizon Pharma USA, Inc.; December 2019. Available at: [www.actimmune.com](http://www.actimmune.com). Accessed December 2, 2020.
- Primary Immunodeficiency
- Immune Deficiency Foundation. Diagnostic and clinical care guidelines for primary immunodeficiency diseases. Third edition. Copyrights 2008, 2009, 2015 the Immune Deficiency Foundation. Available at: [https://primaryimmune.org/sites/default/files/publications/2015-Diagnostic-and-Clinical-Care-Guidelines-for-PI\\_1.pdf](https://primaryimmune.org/sites/default/files/publications/2015-Diagnostic-and-Clinical-Care-Guidelines-for-PI_1.pdf). Accessed December 2, 2020.
- Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. November 2015; 136(5): 1186-1205.
- Osteopetrosis
- Wu CC, Econs MJ, DiMeglio L, et al. Diagnosis and management of osteopetrosis: consensus guidelines from the Osteopetrosis Working Group. J Clin Endocrinol Metab September 2017;102(9):3111–23.

#### **Oncology**

## CLINICAL POLICY

### Interferon Gamma-1b

5. **Interferon Gamma-1b. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [www.nccn.org](http://www.nccn.org). Accessed December 2, 2020.**
6. **National Comprehensive Cancer Network. Primary Cutaneous Lymphomas Version 1.2021. Available at: [www.nccn.org](http://www.nccn.org). Accessed December 2, 2020.**

#### Coding Implications

**Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.**

<u>HCPCS Codes</u>	<u>Description</u>
<b><u>J9216</u></b>	<b><u>Injection, interferon, gamma 1-b, 3 million units</u></b>

<u>Reviews, Revisions, and Approvals</u>	<u>Date</u>
<b><u>Converted corporate to local policy</u></b>	<b><u>06.21</u></b>

#### Important Reminder

**This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.**

**LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.**

**The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results.**

**Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.**

**This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a**

## **CLINICAL POLICY**

### Interferon Gamma-1b

**discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.**

**This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.**

**Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.**

**This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.**

**©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.**